Aatmaj Healthcare Reports FY26 Audited Net Profit of ₹71.34 Lakhs, Revenue Climbs to ₹2,527.33 Lakhs

Aatmaj Healthcare Limited, a Vadodara-based multi-speciality hospital operator listed on the NSE Emerge platform, approved its standalone audited financial results for the year ended March 31, 2026, at a Board of Directors meeting held on May 14, 2026. The results, reviewed by the Audit Committee and audited by Bela Mehta and Associates, Chartered Accountants, received an unmodified audit opinion. The company operates primarily in the business of running multi-speciality hospitals, with all operations based in India.

Financial Performance: FY26 vs FY25

Aatmaj Healthcare recorded steady growth in revenue and profitability for the full year ended March 31, 2026. Revenue from operations increased to ₹2,431.80 lakhs from ₹1,953.34 lakhs in the previous year, while other income stood at ₹95.53 lakhs compared to ₹131.67 lakhs in FY25. Total revenue for FY26 came in at ₹2,527.33 lakhs against ₹2,085.01 lakhs in FY25. Net profit for the year rose to ₹71.34 lakhs from ₹63.92 lakhs in the prior year.

The following table summarises the key financial metrics for the full year:

Metric: FY26 (Audited) FY25 (Audited) Revenue from Operations: ₹2,431.80 lakhs ₹1,953.34 lakhs Other Income: ₹95.53 lakhs ₹131.67 lakhs Total Revenue: ₹2,527.33 lakhs ₹2,085.01 lakhs Total Expenses: ₹2,430.39 lakhs ₹1,977.94 lakhs Profit Before Tax: ₹96.94 lakhs ₹107.07 lakhs Current Tax: ₹22.00 lakhs ₹36.00 lakhs Deferred Tax: ₹4.03 lakhs ₹7.15 lakhs Net Profit: ₹71.34 lakhs ₹63.92 lakhs Basic EPS (₹): 0.32 0.28 Diluted EPS (₹): 0.32 0.28 Paid-Up Equity Share Capital: ₹1,130.00 lakhs ₹1,130.00 lakhs

Half-Year Performance Breakdown

For the six months ended March 31, 2026, the company reported total revenue of ₹1,402.32 lakhs and a net profit of ₹19.84 lakhs. This compares to total revenue of ₹1,125.01 lakhs and net profit of ₹51.07 lakhs for the six months ended September 30, 2025, and total revenue of ₹1,158.49 lakhs with net profit of ₹33.29 lakhs for the six months ended March 31, 2025. The face value of each equity share remained at ₹5 across all periods.

Balance Sheet and Key Ratios

As at March 31, 2026, total assets stood at ₹7,664.56 lakhs compared to ₹6,325.06 lakhs as at March 31, 2025. Shareholders' funds comprised share capital of ₹1,130.00 lakhs and reserves and surplus of ₹3,953.47 lakhs. Long-term borrowings increased to ₹879.71 lakhs from ₹156.09 lakhs, while short-term borrowings rose to ₹1,223.51 lakhs from ₹850.22 lakhs. Cash and cash equivalents at the end of the period were ₹1,169.50 lakhs, compared to ₹1,216.23 lakhs at the beginning of the period.

Key financial ratios for FY26 compared to FY25 are presented below:

Ratio: FY25 FY26 Variance Current Ratio: 4.24 2.90 -31.60% Debt-Equity Ratio: 0.20 0.45 125.00% Debt Service Coverage Ratio: 2.77 2.23 -19.49% Return on Equity Ratio: 0.01 0.01 0.00% Inventory Turnover Ratio: 3.66 2.28 -37.70% Trade Receivables Turnover Ratio: 0.86 0.99 15.12% Trade Payables Turnover Ratio: 1.84 2.17 17.93% Net Capital Turnover Ratio: 0.57 0.80 40.35% Net Profit Ratio (%): 3.27% 2.93% -0.34% Return on Capital Employed: 0.04 0.05 25.00% Return on Investment (%): 1.28% 1.40% 0.12%

IPO Proceeds: Full Utilisation Confirmed

The company confirmed complete utilisation of its IPO proceeds totalling ₹3,840.00 lakhs as on March 31, 2026. The equity shares of Aatmaj Healthcare have been listed on the NSE Emerge platform with effect from June 30, 2023. The utilisation details, as verified by the statutory auditors, are as follows:

Object: Amount in Offer Document (₹ Lakhs) Actual Utilised as on 31/03/2026 (₹ Lakhs) Repayment/Prepayment of existing secured debt: 900.00 900.00 Funding working capital requirements: 600.00 600.00 Purchase of medical equipment for hospitals: 913.11 913.11 Inorganic growth initiatives and acquisitions: 620.00 620.00 General Corporate Expenses: 496.89 496.89 Issue Expenses: 310.00 310.00 Total: 3,840.00 3,840.00

It is noted that the Board of Directors sought and received member approval by way of Special Resolution dated May 27, 2025, for variation in the objects of the prospectus dated June 13, 2023, permitting the utilisation of IPO proceeds amounting to ₹913.11 lakhs for the purchase of medical equipment in lieu of working capital requirements. The Special Resolution was approved by members through remote e-voting, which concluded on June 28, 2025, with a scrutiniser's report submitted to NSE on the same date. As on March 31, 2026, there is nil amount pending to be utilised from the IPO proceeds.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.